Institution statistics

BAYER PHARMA AG - Germany 

This institution has been merged with: BAYER.

Ranking results:

Past rankings:
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2014
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Ranking timeline:

European project participation (2000-01-01 - 2020-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 13
As coordinator: 0
As participant: 13
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2018 0 2.795.346 0 1
2017 0 32.200.000 0 2
2016 0 21.085.937 0 2
2015 0 6.463.625 498.433 2
2014 0 4.000.000 400.000 1
2013 0 3.935.721 95.400 1
2011 0 12.766.589 638.857 3
2005 0 11.998.527 285.679 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
MEDIZINISCHE UNIVERSITAET WIEN5
JANSSEN PHARMACEUTICA NV4
GENOME RESEARCH3
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE3
KAROLINSKA INSTITUTE3
KATHOLIEKE UNIVERSITEIT LEUVEN3
NOVARTIS PHARMA3
NOVO NORDISK3
SANOFIAVENTIS DEUTSCHLAND3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD3
ABBVIE INC2
ACADEMISCH ZIEKENHUIS GRONINGEN2
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
ASTELLAS PHARMA EUROPE BV2
ASTRAZENECA AB2
CANCER RESEARCH UK2
CHARITE UNIVERSITAETSMEDIZIN BERLIN2
ELI LILLY AND COMPANY LIMITED2
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM2
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL2
F HOFFMANNLA ROCHE2
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR2
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT2
KUNGLIGA TEKNISKA HOEGSKOLAN2
LUNDS UNIVERSITET2
MERCK SHARP & DOHME CORP2
PFIZER LIMITED2
TAKEDA DEVELOPMENT CENTRE EUROPE2
UNIVERSIDAD DE NAVARRA2
UNIVERSITA DEGLI STUDI DI TORINO2
UNIVERSITATSKLINIKUM ERLANGEN2
UNIVERSITEIT MAASTRICHT2
UNIVERSITY COLLEGE LONDON2
UNIVERSITY OF HELSINKI2
UNIVERSITY OF LEEDS2
UNIVERSITY OF NEWCASTLE UPON TYNE2
UNIVERSITY OF TURKU2
ABBVIE1
ABBVIE DEUTSCHLAND GMBH & CO KG1
ACTELION PHARMACEUTICALS1
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS1
AMGEN1
AMGEN LIMITED1
ANTAROS MEDICAL AB1
ARISTOTLE UNIVERSITY OF THESSALONIKI1
ARTTIC IN BRUSSELS SPRL1
ASSOCIATION POUR LA RECHERCHE DE THERAPEUTIQUES INNOVANTES EN CANCEROLOGIE1
AVENTIS PHARMA RECHERCHEDEVELOPPEMENT1
AXCENTUA PHARMACEUTICALS AB1
BARTS AND THE LONDON NHS TRUST1
BIOWISDOM LIMITED1
BIOXYDYN LIMITED1
BOEHRINGER INGELHEIM PHARMA GMBH & CO KG1
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG1
BRUKER BIOSPIN MRI1
BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE1
CAPSANT NEUROTECHNOLOGIES1
CELGENE MANAGEMENT SARL1
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE1
CEREBRICON1
CHALMERS TEKNISKA HOEGSKOLA AB1
CHRISTIANALBRECHTSUNIVERSITAET ZU KIEL1
CHU HOPITAUX DE BORDEAUX1
CIPHERGEN BIOSYSTEMS INC1
CONCENTRIS RESEARCH MANAGEMENT1
CSL BEHRING1
DANMARKS TEKNISKE UNIVERSITET1
DEPARTMENT OF OLD AGE PSYCHIATRY & PSYCHOTIC DISORDERS MEDICAL UNIVERSITY OF LODZ1
DSM MATERIALS SCIENCE CENTER BV1
DSM R & D SOLUTIONS BV1
ELI LILLY AND COMPANY1
ERASMUS UNIVERSITEIT ROTTERDAM1
ERNSTMORITZARNDTUNIVERSITAET GREIFSWALD1
EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL1
EUROPEAN CANCER PATIENT COALITION1
EUROPEAN FEDERATION FOR PHARMACEUTICAL SCIENCES1
EUROPEAN FEDERATION OF BIOTECHNOLOGY1
EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS1
EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION1
EUROPEAN HEMATOLOGY ASSOCIATION1
EUROPEAN MOLECULAR BIOLOGY LABORATORY1
EUROPEAN PATIENTS' FORUM1
EUROPEAN RESEARCH INITIATIVE ON CLL EV1
EUTOX WORKING GROUP OF THE ""EUROPEAN SOCIETY OF ARTIFICIAL ORGANS""1
EXPERIMENTAL PHARMACOLOGY AND ONCOLOGY BERLINBUCH1
FEDERAAL KENNISCENTRUM VOOR DE GEZONDHEIDSZORG1
FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS1
FRESENIUS MEDICAL CARE DEUTSCHLAND1
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS1
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALLHEBRON1
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III1
FUNDACION HOSPITAL LA FE1
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON1
GE HEALTHCARE LIMITED1
GENEDATA1
GILUPI1
GMV SOLUCIONES GLOBALES INTERNET SAU1
GPOH GEMEINNUTZIGE1
GROUP FOR RESEARCH ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA1
GROUPE FRANCOPHONE DES MYELODYSPLASIES1
Constancy:

Total number of partners:262

Partner loyalty:
Frequent Partner: (> 2 projects): 33
Rare Partner: 229

Frequent / Rare Partner Ratio: 0.14

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES5
RTD HORIZONTAL TOPICS2
SOCIAL AND ECONOMIC CONCERNS1

Project overview:

Start dateProjectacronymrolefundingpartners
2018-01-01Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease CaReSyAnparticipant2.795.34616
2017-01-01Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 IB4SD-TRISTANparticipant12.000.00021
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-09-01Biomarker Enterprise to Attack DKD - Sofia ref.: 115974 BEAt-DKDparticipant15.085.93731
2015-10-01European Network linking informatics and genomics of helper T cells ENLIGHT-TENparticipant3.354.68511
2015-01-01Improving Design, Evaluation and Analysis of early drug development Studies IDEASparticipant3.108.9398
2014-01-01A CANcer Development mOnitor CanDoparticipant4.000.00010
2013-01-01RADical reduction of OXidative stress in cardiovascular diseases RADOXparticipant3.935.7219
2011-10-01Ion Transport Proteins in Control of Cancer Cell Behaviour IonTraCparticipant3.925.58010
2011-02-01Targeting the tumour microenvironment to improve pancreatic cancer prognosis EPC-TM-Netparticipant3.000.00017
2011-01-01Predicting individual response and resistance to VEGFR/mTOR pathway therapeutic intervention using biomarkers discovered through tumour functional genomics PREDICTparticipant5.841.00914
2005-10-01Innovative medicines for europe INNOMEDparticipant11.998.52742
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum